Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Application of extracellular vesicles in treatment of nerve injury erectile dysfunction

A technology for erectile dysfunction and nerve damage, applied in the field of biomedicine, can solve problems such as large side effects and poor effects, and achieve the effects of easy operation, improvement of erectile function, and convenient use

Pending Publication Date: 2022-01-14
RENJI HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] The technical problem to be solved by the present invention is: the medicines used for treating erectile dysfunction in the prior art have problems such as large side effects and poor effect

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of extracellular vesicles in treatment of nerve injury erectile dysfunction
  • Application of extracellular vesicles in treatment of nerve injury erectile dysfunction
  • Application of extracellular vesicles in treatment of nerve injury erectile dysfunction

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0021] An extracellular vesicle for the treatment of erectile dysfunction:

[0022] 1. Extraction of extracellular vesicles after melatonin pretreatment of human mesenchymal stem cells:

[0023] Obtain P4 adipose-derived mesenchymal stem cells from human autologous tissues or cell banks and culture them in clinical-grade serum-free medium. When the cell fusion reaches 80-90%, add serum-free DMEM medium containing 1 μM melatonin for 24 hours Then collect the cell supernatant. The cell supernatant was centrifuged at 300g for 10min at 4°C, 16500g for 10min at 4°C to remove cells and cell debris, and 120000g for 70min at 4°C to collect extracellular vesicles.

[0024] Wherein, the human mesenchymal stem cells used above are not limited to adipose-derived mesenchymal stem cells, bone marrow-derived mesenchymal stem cells, umbilical cord mesenchymal stem cells, placental mesenchymal stem cells, urine-derived mesenchymal stem cells, etc.; The obtained extracellular vesicles include...

Embodiment 2

[0029] Treatment of nerve-injured erectile dysfunction in Sprague-Dawley rats:

[0030] (1) Take the extracellular vesicles of the human adipose-derived mesenchymal stem cells pretreated with melatonin for injection prepared in Example 1.

[0031] (2) A nerve-injured erectile dysfunction model was constructed on 8-week-old Sprague-Dawley rats, and 100 microliters of the above-mentioned melatonin-pretreated human adipose-derived mesenchymal stem cells were injected into the corpus cavernosum of each rat. extracellular vesicles.

[0032] (3) After 4 weeks of treatment, the erectile function of the rats was evaluated, the intracavernous pressure (ICP) and mean arterial pressure (MAP) of the penis were measured, and the ratio of the two was calculated.

[0033] Depend on image 3 It can be seen that the ICP / MAP indicators representing erectile function were significantly improved ( P image 3 A), using phosphate buffered saline (PBS) as a control after 4 weeks of treatment, the ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an application of extracellular vesicles in treatment of nerve injury erectile dysfunction. The invention provides an application of extracellular vesicles extracted from in-vitro human mesenchymal stem cells pretreated by melatonin in treatment of nerve injury erectile dysfunction for the first time. The extracellular vesicles are dissolved in a phosphate buffer solution to obtain an injection with the concentration of 5*10<10> particles per milliliter. Animal model experiments show that compared with extracellular vesicles which are derived from human mesenchymal stem cells and are not pretreated by melatonin, the extracellular vesicles extracted from the human mesenchymal stem cells pretreated by the melatonin have stronger effects of promoting vascular endothelial repair and nerve regeneration, and can better promote erectile function recovery. The invention solves the technical problem of penis vascular endothelium and nerve injury of patients with refractory erectile dysfunction, and provides a safe, effective and convenient therapeutic pharmaceutical preparation for treating erectile dysfunction.

Description

technical field [0001] The invention relates to the application of an extracellular vesicle in the treatment of erectile dysfunction caused by nerve injury, and belongs to the technical field of biomedicine. Background technique [0002] The current first-line treatment for erectile dysfunction is oral phosphodiesterase-5 inhibitors, such as tadalafil, sildenafil, etc. The main structure of this type of drug is a non-selective or selective phosphodiesterase-5 inhibitor. The principle of treating erectile dysfunction is to increase the concentration of cyclic guanosine monophosphate by inhibiting the activity of penile phosphodiesterase-5 and reducing degradation. The current clinical first-line treatment for erectile dysfunction, phosphodiesterase-5 inhibitors, depends on the integrity of the vascular endothelium, and cannot reverse the damage and injury of the vascular endothelium and nerves. Obstacles and other clinical treatment effects are uncertain. As the second-line...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K35/28A61K9/00C12N5/073C12N5/0775A61P15/10
CPCA61K35/28A61K9/0019A61K9/0034A61P15/10C12N5/0663C12N5/0665C12N5/0668C12N5/0605C12N2500/90
Inventor 卢慕峻杨孟波肖冬冬陈信达张明燕浩吕向国
Owner RENJI HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com